Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ALT

DatePrice TargetRatingAnalyst
1/8/2025$18.00Buy
Stifel
11/12/2024$26.00Buy
UBS
4/29/2024Buy → Neutral
Guggenheim
1/24/2024$13.00Neutral
Goldman
3/22/2023$20.00 → $6.00Buy → Neutral
Goldman
12/1/2022$20.00Buy
Goldman
12/29/2021$30.00Buy
Jefferies
6/30/2021$41.00 → $21.00Buy
B. Riley Securities
More analyst ratings

$ALT
Press Releases

Fastest customizable press release news feed in the world

See more
  • Altimmune to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on February 27, 2025

    GAITHERSBURG, Md., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year 2024 financial results on Thursday, February 27, 2025. Altimmune management will host a conference call at 8:30 am E.T. on February 27 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune's Investor Relations website at https://ir.altimmune.com/investors. Participants who would like to join the call may register here to receive the dial-in numbers and unique PIN to access the call. Shortly after the call, a replay will be available on

    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Altimmune to Participate in the Guggenheim SMID Cap Biotech Conference

    GAITHERSBURG, Md., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference. Details are as follows:  Conference:Guggenheim SMID Cap Biotech Conference    Date/Time:Wednesday, February 5, 2025, at 9:30 a.m. EST    The session will be webcast and can be accessed by visiting the Events section of the Altimmune website. About Altimmune Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is

    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Altimmune Added to Nasdaq Biotechnology Index

    GAITHERSBURG, Md., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that it will be added to the Nasdaq Biotechnology Index (NASDAQ:NBI) effective prior to the market open on Monday, December 23, 2024. "Our addition to the NBI is an important recognition to conclude what has been a year of major progress for the Company," said Vipin K. Garg, Ph.D., President and Chief Executive Officer of Altimmune. "With a number of significant inflection points coming in 2025, including the topline data from the Phase 2b IMPACT trial of pemvidutide in MASH in the second quarter, we believe that we are well positioned heading into

    $ALT
    $IBB
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ALT
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$ALT
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$ALT
SEC Filings

See more

$ALT
Leadership Updates

Live Leadership Updates

See more
  • Altimmune Appoints Former GSK Executive Catherine Angell Sohn, Pharm.D. to its Board of Directors

    GAITHERSBURG, Md., March 27, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced the appointment of Catherine Angell Sohn, Pharm.D. to its Board of Directors. "We are delighted to welcome Catherine to our Board of Directors," said Vipin K. Garg, Ph.D., President and Chief Executive Officer. "Her broad experience in the pharmaceutical industry including strategic product development, business development and commercialization will be invaluable to Altimmune as we pursue our mission to develop next generation peptide therapeutics for obesity and liver disease." Dr. Sohn added, "I am very honored and pleased to join the Altimmun

    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Altimmune Appoints Raymond Jordt as Chief Business Officer

    GAITHERSBURG, Md., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced the appointment of Raymond Jordt as Chief Business Officer, effective January 1, 2023. Mr. Jordt succeeds José Ochoa, who is leaving Altimmune to pursue other opportunities. Mr. Jordt is an accomplished executive with over 25 years of experience in the pharmaceutical industry. He joins Altimmune from Eli Lilly and Company, where he spent nearly two decades in various corporate and business development roles, most recently as Head of Transactions. During his tenure at Lilly, he led acquisitions, in/out-licensing, divestitures, collaborations, option

    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • ObsEva Appoints Will Brown as Chief Financial Officer

     Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – December 13, 2021 – ObsEva SA (NASDAQ:OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health, today announced the appointment of Will Brown as Chief Financial Officer and member of the company's Executive Committee, effective January 1, 2022. "We are thrilled to welcome Will, a highly accomplished biopharmaceutical executive with proven business development and financial acumen, to ObsEva's executive team," said Brian O'Callaghan, Chief Executive Officer of ObsEva. "This is an exciting time for ObsEva on the heels of the

    $ALT
    $OBSV
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ALT
Financials

Live finance-specific insights

See more
  • Altimmune to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on February 27, 2025

    GAITHERSBURG, Md., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year 2024 financial results on Thursday, February 27, 2025. Altimmune management will host a conference call at 8:30 am E.T. on February 27 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune's Investor Relations website at https://ir.altimmune.com/investors. Participants who would like to join the call may register here to receive the dial-in numbers and unique PIN to access the call. Shortly after the call, a replay will be available on

    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Altimmune Announces Third Quarter 2024 Financial Results and Provides a Business Update

    Enrollment completed in Phase 2b IMPACT trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH); top-line efficacy data expected in Q2 2025 Successful completion of the obesity End-of-Phase 2 meeting with the FDA Company plans to submit Investigational New Drug (IND) applications for pemvidutide in up to three additional indications beginning Q4 2024 Cash, cash equivalents and short-term investments of $139.4 million on September 30, 2024 Webcast to be held today, November 12, 2024, at 8:30 a.m. ET GAITHERSBURG, Md., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced financial results for

    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Altimmune to Report Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024

    GAITHERSBURG, Md., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that it will report its third quarter 2024 financial results on Tuesday, November 12, 2024 and will provide a business update. Altimmune management will host a conference call at 8:30 am E.T. on November 12 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune's Investor Relations website at https://ir.altimmune.com/investors. Participants who would like to join the call may register here to receive the dial-in numbers and unique PIN to access the call. Shortly after the call, a replay wi

    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ALT
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more